A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)
NCT ID: NCT03230916
Last Updated: 2024-02-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
47 participants
INTERVENTIONAL
2017-11-06
2020-08-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)
NCT02266706
A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)
NCT03217565
A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)
NCT02750761
Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.
NCT04126031
A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI
NCT05826990
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IMI/REL FDC
Imipenem/Cilastatin/Relebactam (IMI/REL) administered as a single fixed 2:1 ratio of imipenem/cilastatin to relebactam, with a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
IMI/REL FDC
IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IMI/REL FDC
IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged from birth to \<18 years old.
* Is hospitalized, currently receiving antibacterial treatment for confirmed or suspected Gram-negative bacterial infection, and expected to require hospitalization until at least 24 hours after completion of study drug administration.
* Is not of reproductive potential; but if of reproductive potential, agrees to avoid becoming pregnant or impregnating a partner from the time of consent through 24 hours after completion of study drug administration.
* Has clinically stable renal function at the time of screening that is judged to be within acceptable ranges.
* Has sufficient intravascular access to receive study drug through an existing peripheral or central line.
Exclusion Criteria
* Female is currently pregnant or breast feeding or has a positive serum β-human chorionic gonadotropin (β-hCG) pregnancy test.
* Has a history of a seizure disorder requiring ongoing treatment with anti-convulsive therapy or prior treatment with anti-convulsive therapy within the last 3 years.
* Has used or plans to use valproic acid or divalproex sodium within 2 weeks prior to screening or at any point between screening and 24 hours after the completion of study drug infusion.
* Has received treatment or plans to receive treatment with any carbapenem antibiotic within 48 hours prior to initiation of study drug infusion or at any point between administration of study drug and the last PK sample collection.
* Has used or plans to use any of the following medications, which are organic anion transporter (OAT) 1 or OAT3 inhibitors, within 1 week prior to screening or at any point between screening and the last PK sample collection: cimetidine, probenecid, indomethacin, mefenamic acid, furosemide or other loop diuretics (eg, bumetanide, torsemide, ethacrynic acid), angiotensin receptor blockers (eg, valsartan), and ketorolac.
* Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 30 days prior to screening.
* Has enrolled previously in the current trial and been discontinued, or has received REL for any other reason.
* Has a current diagnosis of cystic fibrosis, meningitis, or severe sepsis.
* Is expected to survive less than 72 hours after completion of study drug administration.
* Has a history of clinically significant renal, hepatic, or hemodynamic instability.
* Plans to use cardiopulmonary bypass, extracorporeal membrane oxygenation, hemodialysis, or peritoneal dialysis during the study.
* For participants that are 2 to 17 years of age only: weighs outside of the 5th to 95th percentile based on age.
* Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence.
* Has a planned blood transfusion within 24 hours of study drug administration or expected before the end of the PK sampling.
* Has had significant blood loss (≥5% of total blood volume) within 4 weeks before the screening visit.
1 Day
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arkansas Children's Hospital ( Site 1311)
Little Rock, Arkansas, United States
Children's Hospital of Orange County ( Site 1301)
Orange, California, United States
Rady Children's Hospital-San Diego ( Site 1305)
San Diego, California, United States
Our Lady of the Lake Hospital ( Site 1304)
Baton Rouge, Louisiana, United States
St. Louis Children's Hospital ( Site 1322)
St Louis, Missouri, United States
Duke University Medical Center ( Site 1317)
Durham, North Carolina, United States
The Children's Hospital of Philadelphia ( Site 1318)
Philadelphia, Pennsylvania, United States
Seattle Childrens Hospital ( Site 1321)
Seattle, Washington, United States
MHAT Pazardjik AD ( Site 0208)
Pazardzhik, Pazardzhik, Bulgaria
UMHAT Deva Maria. EOOD ( Site 0209)
Burgas, , Bulgaria
UMHAT Dr. Georgi Stranski EAD ( Site 0211)
Pleven, , Bulgaria
UMHAT Kanev AD ( Site 0203)
Rousse, , Bulgaria
UMHAT Kanev AD ( Site 0212)
Rousse, , Bulgaria
Hospital Pablo Tobon Uribe ( Site 0301)
Medellín, Antioquia, Colombia
Hospital General de Medellin Luz Castro de Gutierrez ( Site 0303)
Medellín, Antioquia, Colombia
Fundacion Valle del Lili ( Site 0300)
Cali, Valle del Cauca Department, Colombia
General Hospital of Thessaloniki Hippokrateio ( Site 1402)
Thessaloniki, , Greece
Akershus Universitetssykehus HF ( Site 0903)
Loerenskog, Akershus, Norway
Stavanger Universitetssykehus, Helse Stavanger ( Site 0901)
Stavanger, Rogaland, Norway
St. Olavs Hospital ( Site 0900)
Trondheim, Sor-Trondelag, Norway
Haukeland Universitetssjukehus ( Site 0902)
Bergen, Vestfold, Norway
SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 1002)
Łomianki, Masovian Voivodeship, Poland
Wojewodzki Specjalistyczny Szpital im. Bieganskiego w Lodzi ( Site 1000)
Lodz, Łódź Voivodeship, Poland
SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 1214)
Dnipro, Dnipropetrovsk Oblast, Ukraine
Kharkiv City Children Hospital 16 ( Site 1200)
Kharkiv, Kharkivs’ka Oblast’, Ukraine
Institution of Pediatr Obstetr and Gynec NAMS of Ukraine ( Site 1213)
Kyiv, Kyivska Oblast, Ukraine
Odessa Regional Children Clinical Hospital ( Site 1203)
Odesa, Odesa Oblast, Ukraine
Children City Clinical Hospital ( Site 1215)
Poltava, Poltava Oblast, Ukraine
Zaporizhzhya Regional Clinical Childrens Hospital ( Site 1202)
Zaporizhzhya, Zaporizhzhia Oblast, Ukraine
Bristol Royal Hospital for Children ( Site 1101)
Bristol, Bristol, City of, United Kingdom
University Hospital Southampton NHS Foundation Trust ( Site 1100)
Southampton, Hampshire, United Kingdom
St. Georges University Hospital NHS Foundation Trust ( Site 1103)
London, London, City of, United Kingdom
Great Northern Children s Hospital ( Site 1102)
Newcastle, Newcastle Upon Tyne, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bradley JS, Makieieva N, Tondel C, Roilides E, Kelly MS, Patel M, Vaddady P, Maniar A, Zhang Y, Paschke A, Chen LF. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial. J Clin Pharmacol. 2023 Dec;63(12):1387-1397. doi: 10.1002/jcph.2334. Epub 2023 Sep 2.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-7665A-020
Identifier Type: OTHER
Identifier Source: secondary_id
2016-004328-43
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
7655A-020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.